KemPharm uses its LAT platform technology to discover and develop prodrugs that improve one or more of the attributes of approved drugs, such as susceptibility to abuse, bioavailability and safety.
Based on this approach, we have created a portfolio of product candidates that we believe will offer significant improvements over FDA-approved and widely prescribed drugs.
Selected KemPharm Prodrug Product Candidates
|Product Candidate||Parent Drug||Development Status||Next Milestone||Potential NDA Submission|
|KP415||Methylphenidate (CR)||Clinical||Phase 3 Initiation||2018|
|KP201/IR||Hydrocodone||Clinical||Phase 3 Initiation||2018 with Priority Review|
|KP511/ER||Hydromorphone||Clinical||Phase 3 Initiation||2018 with Priority Review|
Multiple CNS Disorders